Creabilis therapeutics SpA appoints Domenico Criscuolo as Chief Medical Officer

COLLERETTO GIACOSA, Feb 28th - Creabilis therapeutics SpA announced today the appointment of Domenico Criscuolo as Chief Medical Officer, effective February 21st, 2007.

Dr Criscuolo graduated in Medicine at the University of Rome and got a PhD in Haematology and another one in Clinical Oncology. He started working as Clinical Research physician in 1975 at Lepetit. In 1985 he moved to Roche Italy as Head of International Clinical Research and Drug Safety, and activated Phase I-III studies in several therapeutic areas including oncology, inflammation, CNS, gastroenterology,

antimicrobials and antivirals. In 2001 he moved to Novuspharma – a biotec spin off company of Roche - as Global Head of Clinical Development, and activated Phase I –III studies on four NCEs in the oncology area. From 2003 to 2006 he joined the CRO industry, as VP Regional Operations at ICON, where he established the Italian operations in Milano.
He has been President of SSFA, the Italian association of pharma researchers, and President of IFAPP, the International Federation of Pharmaceutical Medicine. He is teacher at Bocconi Business School on Project management and leadership.

Commenting on the announcement, Dr. Silvano Fumero, CEO Creabilis therapeutics, said: “We are very happy that Dr. Domenico Criscuolo has decided to join our company as Chief Medical Officer. The most advanced candidate drug entering in phase I in the next months is CT327, for the topical treatment of psoriasis. The other two projects approaching clinical stage are CT335/336 for the treatment of Behçet's disease and a mutant Box A (CT500) for HMGB1-RAGE pathologies. The support of Domenico Criscuolo and his experience in this important phase of the company will be extremely helpful.”

ABOUT CREABILIS THERAPEUTICS:
CREABILIS Therapeutics is a drug discovery and development biotech company, founded in May 2003 with the aim to discover, select, develop and bring to commercial fruition novel and highly innovative therapeutic agents.
After three years of research activity a considerable, competitive and diversified project/product portfolio has been generated. CREABILIS is today strongly committed to exploit the potential of its discovery assets and to develop its novel proprietary candidate products.
The most advanced project is related to CT327 in the topical treatment of psoriasis: a Phase I clinical trial is planned in 2Q 2007.
For more information about Creabilis Therapeutics visit http://www.creabilistherapeutics.com/